Browsing by Author Ibrahim, Nageatte

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 2 of 2
Issue DateTitleAuthor(s)Citation
2014Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitorsKefford, Richard (Rick); Long, Georgina; Menzies, Alexander Maxwel; Ackerman, Allison; Atkins, Michael; Flaherty, Keith; Gunturi, Anasuya; Hodi, F. Stephen; Ibrahim, Nageatte; Klein, Oliver; Lawrence, Donald; McDermott, David; Sullivan, Ryan; Wang, Wei; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: MedicineOutcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors, Cancer, vol.120, 11, 2014,pp 1695-1701
2017Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trialCarlino, Matteo; Guminski, Alexander; Kong, Benjamin; Lomax, Anna; Long, Georgina; McNeil, Catriona; Menzies, Alexander Maxwel; Atkins, Michael B; Atkinson, Victoria; Cebon, Jonathan Simon; Ebbinghaus, Scot; Fitzharris, Bernie; Hill, A; Hodi, F. Stephen; Hwu, Wen-Jen; Ibrahim, Nageatte; Islam, Mohammed; Jameson, Michael B; Kefford, Richard; Ribas, Antoni; Shu, Xinxin; Srivastava, Archana; Tamjid, Babak; Thompson, John; Westmead Clinical School: Medicine; Northern Clinical School: Medicine; Central Clinical School: Office; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Northern Clinical School: Medicine; Central Clinical School: Medicine; Northern Clinical School: MedicineStandard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial, The Lancet Oncology, vol.18, 9, 2017,pp 1202-1210